An mRNA Vaccine against SARS-CoV-2 – Preliminary Report


This was a phase 1 trial where they tested an mRNA vaccine on 45 patients ages 18 to 55 years old. There were 3 different dose groups, n=15. Each dose group received a total of 2 vaccinations 28 days apart. They found dose appropriate anti-SARS-CoV-2 titer increases. There were some minor side effects “fatigue, chills, headache, myalgia, and pain at the injection site.” These side effects occurred in more than half the participants.

TL;DR Phase 1 trial of 45 patients for an mRNA vaccine induced an anti-SARS-CoV-2 immune response in all participants

Similar Posts